RPC1063: Additional Phase II data

Additional data from the double-blind, international Phase II TOUCHSTONE trial in 197 patients with moderately to severely active UC showed that once-daily 0.5 and 1

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE